Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Abstract Background In the existing next generation sequencing (NGS) system, epidermal growth factor receptor (EGFR) exon 19 deletion-insertion (19delins) is still interpreted into the category of EGFR exon 19 deletion (19del). However, the controversy exists whether the two mutation types have the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yurong Wang, Ruipan Zheng, Peizhu Hu, Ziheng Zhang, Shujing Shen, Xingya Li
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
EGFR exon 19 deletion-insertion
EGFR TKI
Clinical outcomes
Resistance mechanism
NSCLC
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/f563a95006724209905667bab22efc65
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/f563a95006724209905667bab22efc65

Ejemplares similares